

Screening Run-In
100 mg
Placebo
Eosinophil Recovery
8 wks
Screening Period
56 wks
Double-Blind Treatment Period
32 wks
Washout/ Safety Follow-Up

Figure 1



Placebo
N / Rate
Benralizumab
N / Rate
TV
Rate Reduction [95% CI]
Overall (N=101)
50 / 0.91
51 / 0.93
-2% [-51%, 31%]
Peripheral Blood Eos
>= 200 (N=46)
24 / 0.97
22 / 0.63
35% [-24%, 65%]
< 200 (N=53)
25 / 0.78
28 / 1.19
-53% [-162%, 11%]
>= 300 (N=25)
8 / 0.93
17 / 0.33
65% [-2%, 88%]
< 300 (N=74)
41 / 0.86
33 / 1.27
-47% [-127%, 4%]
200 - 300 (N=21)
16 / 0.99
5 / 1.67
-69% [-280%, 24%]
-90
-60
-30
0
30
60
90
Rate Reduction (%)

Figure 2



MEAN FEV1 PREDICTED CHANGE FROM BASELINE (%)
12
10
8
6
4
2
0
-2
-4
-6
-8
-10
D29 D57 D113 D169 D225 D281 D337 D393 D477 D561
PLACEBO (n) 44 44 44 44 44 43 42 44 29 8
Benralizumab (n) 40 40 40 40 40 39 38 37 22 9
VISIT (1)
TREATMENT GROUP: PLACEBO (N-44) Benralizumab 100MG (N-40)

Figure 3

SUBSTITUTE SHEET (RULE 26)




Figure 4



Placebo
N / ESTIMATE
Benralizumab
N / ESTIMATE
Difference [95% CI]
Overall (N=86)
44 / −0.079
42 / 0.047
0.125 [−0.004, 0.254]
Peripheral Blood Eos
>= 200 (N=38)
19 / −0.083
19 / 0.149
0.231 [−0.018, 0.481]
< 200 (N=47)
24 / −0.058
23 / −0.035
0.023 [−0.093, 0.138]
>= 300 (N=20)
6 / −0.127
14 / 0.157
0.284 [−0.169, 0.736]
< 300 (N=65)
37 / −0.055
28 / −0.010
0.045 [−0.061, 0.150]
200 − 300 (N=18)
13 / −0.038
5 / 0.060
0.098 [−0.154, 0.351]
−0.2
0.0
0.2
0.4
0.6
0.8
Difference

Figure 5



Placebo
N / ESTIMATE
Benralizumab
N / ESTIMATE
Difference [95% CI]
Overall (N=86)
46 / -3.957
42 / -3.928
0.030 [-5.315, 5.374]
Peripheral Blood Eos
>= 200 (N=40)
21 / -4.833
19 / -8.233
-3.400 [-12.472, 5.672]
< 200 (N=47)
24 / -3.334
23 / -0.395
2.940 [-3.844, 9.724]
>= 300 (N=22)
8 / -5.969
14 / -11.158
-5.189 [-20.766, 10.387]
< 300 (N=65)
37 / -3.510
28 / -0.444
3.066 [-2.614, 8.746]
200 - 300 (N=18)
13 / -4.543
5 / 1.340
5.883 [-6.395, 18.161]
-35
-25
-15
-5
0
5
10
15
20
Difference

Figure 6





Placebo
N / ESTIMATE
Benralizumab
N / ESTIMATE
Difference [95% CI]
Overall (N=88)
46 / −3.178
42 / −6.264
−3.086 [−9.325, 3.153]
Peripheral Blood Eos
>= 200 (N=40)
21 / −2.725
19 / −13.514
−10.789 [−21.551, −0.027]
< 200 (N=47)
24 / −4.442
23 / −0.102
4.340 [−3.043, 11.724]
>= 300 (N=22)
8 / −2.883
14 / −17.135
−14.251 [−31.734, 3.231]
< 300 (N=65)
37 / −3.546
28 / −0.774
2.771 [−3.532, 9.075]
200 ~ 300 (N=18)
13 / −2.741
5 / −1.499
1.243 [−12.695, 15.180]
−35
−25
−15
−5
0
5
10
15
20
Difference

Figure 7



[1] DATA BEYOND DAY 337 (MARKED BY THE VERTICAL REFERENCE LINE) OCCUR AFTER THE LAST SCHEDULED DOSE OF STUDY DRUG. BSL-BASELINE, DX-DAY X.

Figure 8



[1] DATA BEYOND DAY 337 (MARKED BY THE VERTICAL REFERENCE LINE) OCCUR AFTER THE LAST SCHEDULED DOSE OF STUDY DRUG. BSL-BASELINE, DX-DAY X.

Figure 9




EOSINOPHILS (ABS) (X10E3/UL)
0.40
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0.00
BSL D29 D57 D113 D169 D225 D281 D337 D393 D477 D561
PLACEBO (n) 49 45 45 43 45 43 43 42 43 36 19
Benralizumab (n) 50 48 47 47 47 43 42 41 39 28 17
VISIT (1)
TREATMENT GROUP: PLACEBO (N-50) Benralizumab 100MG (N-51)


Figure 10



11/12

Visit 1 occurs in week -4.
Visit 2 occurs in week -3.
Visit 3 occurs in week -1.
Visit 4 occurs in week 0.
Visits 4-7 occur in weeks 0-8.
Visits 8-18 occur in weeks 12-52.
Visit 19 occurs in week 56.
Visit 20 occurs in week 60.

Figure 11



Visit 1 occurs in week -4.
Visit 2 occurs in week -3.
Visit 3 occurs in week -1.
Visit 4 occurs in week 0.
Visits 4-7 occur in weeks 0-8.
Visits 8-18 occur in weeks 12-52.
Visit 19 occurs in week 56.
Visit 20 occurs in week 60.

Figure 12